February 26, 2019 –
WuXi NextCODE offers access to Illumina's TruSightTM Oncology 500 (TSO 500).
WuXi NextCODE partners are gaining access to Illumina’s TruSightTM Oncology 500 (TSO 500), a comprehensive pan-cancer assay that identifies known and emerging tumor biomarkers.
TSO 500 offers deep, adaptable, and accessible sequencing power:
With the opening of a WuXi NextCODE laboratory in Woburn, MA we are expanding our global CLIA/CAP lab footprint, which already includes Shanghai and Dublin, thereby empowering clinical trial/research testing around the world. Our US lab features a turn-around time of 7-10 calendar days from sample to data for the TSO 500 assay.
WuXi NextCODE’s end-to-end platform includes industry-leading cohort sourcing, sequencing services, advanced analysis, and related tools and services to generate high-value strategic insights needed for diagnostic and drug development.
If you’re interested in using the TSO 500 panel for your next project, contact email@example.com.